Vlad Coric, M.D.
Chief Executive Officer and Director
Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). He has conducted numerous clinical trials in various illnesses including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma. Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association). Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.
Robert Berman M.D.
Chief Medical Officer
Dr. Berman has over 30 years of experience in neuroscience research, both within academia and industry. At the Yale University School of Medicine, he held clinical and research positions at the Connecticut Mental Health Center and the West Haven VA Medical Center. While on faculty at Yale, his work focused on translational research and novel treatments for affective disorders. This work includes the first report on the clinical efficacy of the non-specific glutamate NMDA antagonist, ketamine, in the treatment of depression (Berman et al., 2000). In 2000, Dr. Berman joined Pfizer as an Associate Director of Clinical Sciences where he led multiple programs in Major Depression in the translational medicine and clinical pharmacology group. In 2003, Dr. Berman joined the clinical development group at Bristol-Myer Squibb where he served as a Group Director. His accomplishments there include leading the ABILIFY program in attaining a first-cycle FDA approval for use in major depressive disorder, designing and implementing novel clinical methods (Berman et al., 2007; 2009; 2011; Marcus et al., 2008). Dr. Berman earned his undergraduate degree at Yale University (Molecular Biophysics and Biochemistry) and medical degree at the Mount Sinai School of Medicine, after which he pursued a residency in psychiatry at the Yale School of Medicine. He has over 70 peer-reviewed publications and is an Adjunct Professor at the Yale University School of Medicine, Department of Psychiatry.
Chief Financial Officer
Mr. Engelhart brings to Biohaven 30 years of finance experience including over 17 years within the pharmaceutical industry at Alexion Pharmaceuticals, Bristol-Myers Squibb and Schering-Plough. He joins Biohaven from Alexion Pharmaceuticals where he was Executive Director, Finance of the North America and Latin America Regions, providing financial leadership, strategy, and planning to the regions including two simultaneous Orphan Drug Launches in the US. Previously, Mr. Engelhart’s finance roles have spanned strategic planning and analysis at the Corporate, Commercial, and R&D levels, business restructuring and M&A, two international assignments, and a strong foundation in accounting and internal controls. He began his career at Coopers and Lybrand. Mr. Engelhart is a graduate of Villanova University’s School of Business where he earned a Bachelor of Science degree in Accountancy and is a Certified Public Accountant.
Chief Commercial Officer
Mr. Tilton has over 20 years of experience commercializing drug products and leading global pharmaceutical business units. He joined Biohaven from Alexion Pharmaceuticals, Inc. where he was an Executive Director and one of the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton played a central role in the successful global launches of Soliris, as well as building operational infrastructure, for 4 orphan indication launches in over 30 countries for Alexion. Previously, Mr. Tilton held leadership roles of increasing responsibility at Pfizer, Agouron and Sanofi with therapeutic focus in the orphan, oncology and specialty markets. Mr. Tilton holds a Bachelor of Science degree in Business Administration from the University of South Carolina — Darla Moore School of Business.
Vice President of Operations
Ms. Gentile has more than 26 years experience in the pharmaceutical industry in all phases of clinical research from Phase 1 through Phase 4, predominantly in the areas of psychiatry and neurology. She has deep, hands-on experience in most key operational aspects of drug development, having held positions at small biotechnology companies, contract research organizations, investigative sites as well as small and large pharmaceutical companies. Ms. Gentile spent the previous 14 years in the Clinical Operations group at Bristol-Myers Squibb where she was responsible for operational oversight of large-scale global programs in the areas of psychiatry and neurology, including the management of complex global programs in GAD, Treatment Resistant Depression and Alzheimer’s Disease.She has a proven track record of successfully managing complex and challenging drug development programs within set timelines and budgets.
Douglas G. Gray, Esq.
General Outside Counsel
Mr. Gray is a partner at Locke Lord LLP, a global law firm with over 1,000 lawyers in 23 offices (Corporate and Transactional Department) and concentrates his practice in areas of mergers, acquisitions, corporate governance, strategic alliances, and commercial ventures. He acts as general outside counsel to a number of clients, ranging from large multi-national companies to newly formed companies. His clients range from industrial manufacturers to life science companies. Mr. Gray’s practice involves representation of corporate entities, individuals, management teams, and private equity firms as buyers and sellers. Mr. Gray obtained his Juris Doctorate from University of Notre Dame School of Law and his B.A. from Yale University.